Patent Application
20160015614
The present invention relates to active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically acceptable UV filter substances. Furthermore, the present invention relates to cosmetic or dermatological preparations with a content of such active ingredient combinations, and to the use thereof for lightening human skin.
Melanocytes are responsible for the pigmenting of the skin; these are found in the lowest layer of the epidermis, the Stratum basale, alongside the basal cells as pigment-forming cells which, depending on the skin type, occur either individually or in clusters of varying size.
Melanocytes contain, as characteristic cell organelles, melanosomes, in which the melanin is formed. Inter alia, upon stimulation by UV radiation, melanin is formed to a greater extent. This is transported via the living layers of the epidermis (keratinocytes) ultimately into the horny layer (corneocytes) and brings about a more or less pronounced brownish to brown-black skin color.
Melanin is formed as the end stage of an oxidative process in which tyrosine is converted, under the co-action of the enzyme tyrosinase, via several intermediates, to the brown to brown-black eumelanins (DHICA and DHI melanin), or, with the participation of sulfur-containing compounds, to the reddish pheomelanin. DHICA and DHI melanin are formed via the common intermediates dopaquinone and dopachrome. The latter, sometimes with the participation of further enzymes, is converted either to indol-5,6-quinonecarboxylic acid or into indol-5,6-quinone, from which the two specified eumelanins are formed.
The formation of pheomelanin proceeds inter alia via the intermediates dopaquinone and cysteinyldopa. The expression of the melanin-synthesizing enzymes is controlled by a specific transcription factor (microphthalmia-associated transcription factor, MITF). Besides the described enzymatic processes of the melanin synthesis, further proteins are also of importance for the melanogenesis in the melanosomes. An important role here appears to be attributed to the so-called p-protein, although the exact function is still unclear.
As well as the above-described process of the melanin synthesis in the melanocytes, the transfer of the melanosomes, their stay in the epidermis and also their degradation and the degradation of the melanin are also of decisive importance for the pigmenting of the skin. It was shown that the PAR-2 receptor is important for the transport of the melanosomes from the melanocytes into the keratinocytes (M. Seiberg et al., 2000, J. Cell. Sci., 113:3093-101).
In addition, size and shape of the melanosomes have an influence on their light-scattering properties and thus the color appearance of the skin. For example, in black Africans there are more large spheroidal individual melanosomes, whereas in Caucasians, smaller melanosomes occurring in groups are to be found.
Problems with hyperpigmentation of the skin have a wide variety of causes and/or are accompanying phenomena of many biological processes, e.g. UV radiation (e.g. freckles, Ephelides), genetic disposition, incorrect pigmentation of the skin during wound healing or scarring (post-inflammatory hyperpigmentation) or skin aging (e.g. Lentigines seniles).
After inflammatory reactions, the pigmentation system of the skin reacts with sometimes opposite reactions. This can lead either to post-inflammatory hyperpigmentations or hypopigmentations. Post-inflammatory hypomelanoses often arise inter alia in conjunction with atopy, Lupus erythematosus and psoriasis. The different reaction forms of the pigmentation system of the human skin as a result of inflammatory phenomena are understood only very incompletely.
Problems with post-inflammatory hyperpigmentation often occur in darker skin types. Particularly in colored males, the problem of Pseudofollikulitis barbae is known, which is associated with cosmetically undesired incorrect pigmentation and/or leads to this. Forms of melasma, which occur in particular in women of Asiatic origin on the face and on the décolletage area, and also various forms of irregular pigmentation of the skin are also types of post-inflammatory hyperpigmentations. In addition, dark circles around the eyes are also considered to be a form of post-inflammatory hyperpigmentations, the underlying inflammation in most cases proceeding without clinical manifestations.
In many cases, post-inflammatory incorrect pigmentation of this type is increased further by the action of sunlight (UV light) without resulting in a UV-induced inflammation (sunburn).
Active ingredients and preparations are known which counteract skin pigmentation. In practical use these are essentially preparations based on hydroquinone, although, on the one hand, these only exhibit their effect after application for several weeks, and, on the other hand, their excessively long application is unacceptable for toxicological reasons. Albert Kligman et al. have developed a so-called “triformula” which constitutes a combination of 0.1% tretinoin, 5.0% hydroquinone, 0.1% dexamethasone (A. Kligman, 1975, Arch. Dermatol., 111:40-48). However, this formulation too is highly disputed on account of possible irreversible changes in the pigmentation system of the skin.
In addition, skin-peeling methods (chemical and mechanical “peels”) are used, although these often lead to inflammatory reactions and, on account of post-inflammatory hyperpigmentations which may subsequently arise, can even lead to greater pigmentation instead of reduced pigmentation. All of these customary methods, which are also used for treating post-inflammatory hyperpigmentations, are characterized by distinct side effects.
Furthermore, various other substances are known for which a skin-lightening effectiveness is described. Mention is to be made here inter alia of hexadecene-1,16-dicarboxylic acid, kojic acid and derivatives, arbutin, ascorbic acid and derivatives, flavonoids, ellagic acid and derivatives, tranexamic acid and various resorcinol derivatives, such as e.g. 4-n-butylresorcinol, 4-n-hexylresorcinol and 4-(1-phenylethyl)benzene-1,3-diol. J. M. Ready describes in a publication (Bioorganic & Medicinal Chemistry Letter 17 (2007) 6871-6875) the effect of inter alia substituted thiazole derivatives for the inhibition of Mushroom tyrosinase.
The patent application from Shiseido (WO 2009099195) describes substituted thiazolamines and hydrothiazolamines for lightening skin.
The substances described in the aforementioned prior art are proven by a moderate effectiveness.
Rings around the eyes can likewise be formed as a result of a pigmentation disorder, with them in addition also appearing as a reaction to general stress, such as e.g. too little sleep or simply as a result of overexerting the eyes. In younger people, the symptoms disappear again after an adequate nighttime rest, but, over prolonged periods, the condition can become chronic and very troublesome for those affected. There is also a lack of sufficiently promising active ingredients and treatment options to combat such skin phenomena.
It was therefore an object of the invention below to provide a remedy for the disadvantageous prior art.
This object is achieved by active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically acceptable UV filter substances.
Advantageous embodiments of the present invention are also cosmetic or dermatological preparations with a content of such active ingredient combination, and the use thereof for lightening human skin.
Advantageously, preparations according to the invention comprise substances which absorb UV radiation in the UV-A and/or UV-B region, where the total amount of the filter substances is e.g. 0.01% by weight to 30% by weight, preferably 0.05 to 20% by weight, in particular 0.1 to 15.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair and/or the skin from the entire range of ultraviolet radiction. They can also serve as sunscreens for the hair or the skin.
In the context of the present invention, advantageous UV-A filter substances are dibenzoylmethane derivatives, in particular 4-(tert-butyl)-4′-methoxydibenzoylmethane (CAS No. 70356-09-1), which is sold by Givaudan under the trade name Parsol® 1789 and by Merck under the trade name Eusolex® 9020.
Further advantageous UV-A filter substances are phenylene-1,4-bis(2-benzimidazyl)-3,3′-5,5′-tetrasulfonic acid
and its salts, particularly the corresponding sodium, potassium or triethanolammonium salts, in particular phenylene-1,4-bis(2-benzimidazyl)-3,3′-5,5′-tetrasulfonic acid bis-sodium salt
with the INCI name Bisimidazylate, which is available for example under the trade name Neo Heliopan AP from Haarmann & Reimer.
Also advantageous are 1,4-di(2-oxo-10-sulfo-3-bornylidenemethyl)benzene and salts thereof (particularly the corresponding 10-sulfato compounds, in particular the corresponding sodium, potassium or triethanolammonium salt), which is also referred to as benzene-1,4-di(2-oxo-3-bornylidenemethyl-10-sulfonic acid) and is distinguished by the following structure:
Advantageous UV filter substances in the context of the present invention are also so-called broadband filters, i.e. filter substances which absorb both UV-A and UV-B radiation.
Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyltriazine derivatives with the following structure:
where R1, R2 and R3, independently of one another, are selected from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms or are an individual hydrogen atom. Particular preference is given to 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Aniso Triazine), which is available under the trade name Tinosorb® S from CIBA-Chemikalien GmbH, and 4,4′,4″-(1,3,5-triazine-2,4,6-triyltriimino)trisbenzoic acid tris(2-ethylhexyl ester), synonym: 2,4,6-tris[anilino-(p-carbo-2′-ethyl-1-hexyloxy)]-1,3,5-triazine (INCI: Octyl Triazone), which is sold by BASF Aktiengesellschaft under the trade name UVINUL® T 150.
Other UV filter substances which have the structural motif
are also advantageous UV filter substances in the context of the present invention, for example the s-triazine derivative described in the European laid-open specification EP 570 838 A1, the chemical structure of which is given by the generic formula
where
R is a branched or unbranched C1-C18-alkyl radical, a C5-C12-cycloalkyl radical, optionally substituted with one or more C1-C4-alkyl groups,
X is an oxygen atom or an NH group,
R1 is a branched or unbranched C1-C18-alkyl radical, a C5-C12-cycloalkyl radical, optionally substituted with one or more C1-C4-alkyl groups, or is a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
in which
A is a branched or unbranched C1-C18-alkyl radical, a C5-C12-cycloalkyl or aryl radical, optionally substituted with one or more C1-C4-alkyl groups,
R3 is a hydrogen atom or a methyl group,
n is a number from 1 to 10,
R2 is a branched or unbranched C1-C18-alkyl radical, a C5-C12-cycloalkyl radical, optionally substituted with one or more C1-C4-alkyl groups, if X is the NH group, and
a branched or unbranched C1-C18-alkyl radical, a C5-C12-cycloalkyl radical, optionally substituted with one or more C1-C4-alkyl groups, or is a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
in which
A is a branched or unbranched C1-C18-alkyl radical, a C5-C12-cycloalkyl or aryl radical, optionally substituted with one or more C1-C4-alkyl groups,
R3 is a hydrogen atom or a methyl group,
n is a number from 1 to 10,
if X is an oxygen atom.
In the context of the present invention, a particularly preferred UV filter substance is also an asymmetrically substituted s-triazine, the chemical structure of which is given by the formula
which is referred to hereinbelow also as dioctylbutylamidotriazone (INCI: dioctylbutamidotriazone) and is available under the trade name UVASORB HEB from Sigma 3V.
The European laid-open specification 775 698 also describes bis-resorcinyltriazine derivatives to be used with preference, the chemical structure of which is given by the generic formula:
where R1, R2 and A1 represent a very wide variety of organic radicals.
Also advantageous in the context of the present invention are 2,4-bis{[4-(3-sulfonato)-2-hydroxypropyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine sodium salt, 2,4-bis{[4-(3-(2-propyloxy)-2-hydroxypropyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-[4-(2-methoxyethylcarboxyl)phenylamino]-1,3,5-triazine, 2,4-bis{[4-(3-(2-propyloxy)-2-hydroxypropyloxy)-2-hydroxy]phenyl}-6-[4-(2-ethylcarboxyl)phenylamino]-1,3,5-triazine, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1-methyl-pyrrol-2-yl)-1,3,5-triazine, 2,4-bis{[4-tris(trimethylsiloxysilylpropyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis{[4-(2″-methylpropenyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine and 2,4-bis{[4-(1′,1′,1′,3′,5′,5′,5′-heptamethylsiloxy-2″-methylpropyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine.
An advantageous broadband filter in the context of the present invention is 2,2′-methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol), which is characterized by the chemical structural formula
and is available under the trade name Tinosorb® M from CIBA-Chemikalien GmbH.
An advantageous broadband filter in the context of the present invention is also 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]phenol (CAS No.: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is characterized by the chemical structural formula
The UV-B filters can be oil-soluble or water-soluble. Advantageous oil-soluble UV-B filter substances are e.g.: 3-benzylidenecamphor derivatives, preferably 3-(4-methylbenzylidene)camphor, 3-benzylidenecamphor; 4-aminobenzoic acid derivatives, preferably 2-ethylhexyl 4-(dimethylamino)benzoate, amyl 4-(dimethylamino)benzoate; 2,4,6-trianilino(p-carbo-2′-ethyl-1′-hexyloxy)-1,3,5-triazine; esters of benzalmalonic acid, preferably di(2-ethylhexyl) 4-methoxybenzalmalonate; esters of cinnamic acid, preferably 2-ethylhexyl 4-methoxycinnamate, isopentyl 4-methoxycinnamate; derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4′-methylbenzophenone, 2,2′-dihydroxy-4-methoxybenzophenone, and UV filters bonded to polymers.
Advantageous water-soluble UV-B filter substances are e.g. salts of 2-phenylbenzimidazol-5-sulfonic acid, such as its sodium, potassium or triethanolammonium salt, and also the sulfonic acid itself; sulfonic acid derivatives of 3-benzylidenecamphor, such as e.g. 4-(2-oxo-3-bornylidenemethyl)benzenesulfonic acid, 2-methyl-5-(2-oxo-3-bornylidenemethyl)sulfonic acid and salts thereof.
A further light protection filter substance to be used advantageously according to the invention is ethylhexyl 2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul® N 539 and is characterized by the following structure:
It may also be of considerable advantage to use polymer-bonded or polymeric UV filter substances in preparations according to the present invention, in particular those as are described in WO-A-92/20690.
Furthermore, it may optionally be advantageous in accordance with the invention to incorporate further UV-A and/or UV-B filters into cosmetic or dermatological preparations, for example certain salicylic acid derivatives such as 4-isopropylbenzyl salicylate, 2-ethylhexyl salicylate (=octyl salicylate), homomenthyl salicylate.
Preparations according to the invention characterized in that the UV-light-absorbing substance or substances is or are selected from the group butylmethoxydibenzoylmethane, ethylhexyl methoxycinnamate, octocrylene, ethylhexyl salicylate, phenylbenzimidazolesulfonic acid, disodium phenyldibenzimidazoletetrasulfonate, benzophenone-3, drometrizole trisiloxane, benzophenone-4, homosalate, benzene-1,4-di(2-oxo-3-bornylidenemethyl-10-sulfonic acid, polysilicone-15, ethylhexyl triazone, diethylhexyl-butamidotriazone, isoamyl p-methoxycinnamate, diethylamino hydroxybenzoyl hexyl benzoate, methylenebisbenzotriazolyltetramethylbutylphenol, bis-ethylhexyloxyphenolmethoxyphenyltriazine, 4-methylbenzylidenecamphor, 2,4-bis[5-](dimethylpropyl)benzoxazol-2-yl(4-phenyl)imino]-6-(2-ethylhexyl)imino-1,3,5-triazine and/or (2-{4-[2-(4-diethylamino-2-hydroxybenzoyl)benzoyl]piperazine-1-carbonyl}phenyl)-(4-diethylamino-2-hydroxyphenyl)methanone are very particularly advantageous.
Advantageously, the preparations according to the invention comprise 0.01-30% by weight of one or more UV-light-absorbing substances, preferably 0.05-20% by weight of one or more UV-light-absorbing substances, particularly preferably 0.1-15% by weight of one or more UV-light-absorbing substances.
Of advantage are in particular preparations or uses according to the invention, characterized in that the preparations comprise 0.000001 to 10% by weight, in particular 0.0001 to 3% by weight, very particularly 0.001 to 1% by weight of one or more alkylamidothiazoles, based on the total weight of the composition.
Advantageous alkylamidothiazoles in the context of the present invention are substances of the general formula
in which
R1, R2, X and Y can be different, partly identical or completely identical and, independently of one another, can mean:
R1=—C1-C24-alkyl (linear and branched), —C1-C24-alkenyl (linear and branched), —C1-C8-cycloalkyl, —C1-C8-cycloalkyl-alkylhydroxy, —C1-C24-alkylhydroxy (linear and branched), —C1-C24 alkylamine (linear and branched), —C1-C24-alkylaryl (linear and branched), —C1-C24-alkylaryl-alkyl-hydroxy (linear and branched), —C1-C24-alkylheteroaryl (linear and branched), —C1-C24-alkyl-O—C1-C24-alkyl (linear and branched), —C1-C24 alkyl-morpholino, —C1-C24 alkyl-piperidino, —C1-C24 alkyl-piperazino, —C1-C24 alkyl-piperazino-N-alkyl,
R2=H, —C1-C24-alkyl (linear and branched), —C1-C24-alkenyl (linear and branched), —C1-C8-cycloalkyl, —C1-C24-hydroxyalkyl (linear and branched), —C1-C24-alkylaryl (linear and branched), —C1-C24-alkylheteroaryl (linear and branched),
X=—H, —C1-C24-alkyl (linear and branched), —C1-C24-alkenyl (linear and branched), —C1-C8-cycloalkyl, —C1-C24-aryl (optionally mono- or polysubstituted with —OH, —F, —Cl, —Br, —I, —OMe, —NH2, —CN), —C1-C24-heteroaryl (optionally mono- or polysubstituted with —OH, —F, —Cl, —Br, —I, —OMe, —NH2, —CN), —C1-C24-alkylaryl (linear and branched), —C1-C24-alkylheteroaryl (linear and branched), -aryl (optionally mono- or polysubstituted with —OH, —F, —Cl, —Br, —I, —OMe, —NH2, —CN), -phenyl, -2,4-dihydroxyphenyl, -2,3-dihydroxyphenyl, -2,4-dimethoxyphenyl, -2,3-dimethoxyphenyl,
Y=H, —C1-C24-alkyl (linear and branched), —C1-C24-alkenyl (linear and branched), —C1-C8-cycloalkyl, —C1-C24-aryl, —C1-C24-heteroaryl, —C1-C24-alkylaryl (linear and branched), —C1-C24-alkylheteroaryl (linear and branched), -aryl, -phenyl, -2,4-dihydroxyphenyl, -2,3-dihydroxyphenyl, -2,4-dimethoxyphenyl, -2,3-dimethoxyphenyl, —COO-alkyl, —COO-alkenyl, —COO-cycloalkyl, —COO-aryl, —COO-heteroaryl,
and X, Y can optionally also=condensed aromatic,
where X and Y can form with one another aromatic or aliphatic homo- or heterocyclic ring systems with up to n ring-forming atoms, and where the number n can assume values from 5 to 8, and the respective ring systems can in turn be substituted with up to n−1 alkyl groups, hydroxyl groups, carboxyl groups, amino groups, nitrile functions, sulfur-containing substituents, ester groups and/or ether groups.
Said thiazoles can either be in the form of the free base or the salt: e.g. fluoride, chloride, bromide, iodide, sulfate, carbonate, ascorbate, acetate or phosphate. In particular in the form of halogen salts, such as e.g. chloride and bromide.
Furthermore, there is an advantageous realization of the present invention in cosmetic or dermatological preparations with an effective content of one or more aforementioned alkylamidothiazoles.
Also in accordance with the invention is the use of the aforementioned alkylamidothiazoles for the treatment and/or prophylaxis of undesired skin pigmentation.
Here, treatment and/or prophylaxis of undesired skin pigmentation can be both in the cosmetic sphere and in the pharmaceutical sphere.
In this connection, the pharmaceutical (or dermatological) treatment is primarily understood for diseased skin conditions, whereas the cosmetic treatment and/or prophylaxis of undesired skin pigmentation primarily relates to healthy skin.
Advantageously, X is selected from the group of substituted phenyls, in which case the substituents (Z) can be selected from the group —H, —OH, —F, —Cl, —Br, —I, —OMe, —NH2, —CN, acetyl and can be identical or different.
Particularly advantageously, X is selected from the group of phenyl groups substituted with one or more hydroxy groups, in which case the substituent (Z) can be selected from the group —H, —OH, —F, —Cl, —Br, —I, —OMe, —NH2, —CN, acetyl, and preference is given to the following generic structure in which Y, R1 and R2 can have the properties defined above.
Particularly advantageous compounds are those in which
R1=—C1-C24-alkyl (linear and branched), —C1-C24-alkenyl (linear and branched), —C1-C8-cycloalkyl, —C1-C8-cycloalkyl-alkylhydroxy, —C1-C24 alkylhydroxy (linear and branched), —C1-C24 alkylamine (linear and branched), —C1-C24-alkylaryl (linear and branched), —C1-C24-alkylaryl-alkyl-hydroxy (linear and branched), —C1-C24-alkylheteroaryl (linear and branched), —C1-C24-alkyl-O—C1-C24-alkyl (linear and branched), —C1-C24-alky-morpholino, —C1-C24 alkyl-piperidino, —C1-C24 alkyl-piperazino, —C1-C24 alkyl-piperazino-N-alkyl,
R2=H, —C1-C24-alkyl (linear and branched),
Z=—H, —OH, —F, —Cl, —Br, —I, —OMe, —NH2, —CN, acetyl.
Particular preference is given to those compounds in which
R1=—C1-C24-alkyl (linear and branched), —C1-C24-alkenyl (linear and branched), —C1-C8-cycloalkyl, —C1-C8-cycloalkyl-alkylhydroxy, —C1-C24-alkylhydroxy (linear and branched), —C1-C24 alkylamine (linear and branched), —C1-C24-alkylaryl (linear and branched), —C1-C24-alkylaryl-alkyl-hydroxy (linear and branched), —C1-C24-alkylheteroaryl (linear and branched), —C1-C24-alkyl-O—C1-C24-alkyl (linear and branched), —C1-C24 alkyl-morpholino, —C1-C24 alkyl-piperidino, —C1-C24 alkyl-piperazino, —C1-C24 alkyl-piperazino-N-alkyl,
R2=H.
The compounds
are preferred according to the invention.
Surprisingly, it was possible to show that the alkylamidothiazoles according to the invention in combination with UV filters according to the invention have an increased effectiveness.
Method Description of the Effectiveness Investigations:
The effectiveness of the thiazoles was demonstrated using an enzyme test in which conversion of L-DOPA to L-dopaquinone by a human tyrosinase was measured. In this literature-known method (Winder, A. J. and Harris, H., New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase. Eur. J. Biochem. (1991), 198, 317-26), the reaction product L-dopaquinone is reacted with MBTH (3-methyl-2-benzothiazoline hydrazone) to give a pink-colored substance, the increase of which is measured over time by absorption at 490 nm. Table 1 shows by way of example effectiveness data for some of the claimed substances. It can be concluded from this that the substances according to the invention are extremely effective pigmentation-inhibiting substances.
Synthesis procedures of alkylamidothiazoles selected by way of example:
Mitchell, David; Doecke, Christopher W.; Hay, Lynne A.; Koenig, Thomas M.; Wirth, David D. Tetrahedron Letters, 1995
A solution of 60 g (369 mmol) of 2,4-dihydroxyacetophenone and 186 ml of triethylamine in 900 ml of tetrahydrofuran was cooled to 0° C., and 93 ml of methyl chloroformate in 400 ml of tetrahydrofuran was slowly added dropwise. A white precipitate is formed. After stirring for 3 hours at room temperature, the reaction is complete (TLC control). The precipitate was filtered off with suction and washed with copious amounts of tetrahydrofuran. The filtrate was evaporated to dryness on a rotary evaporator, taken up in ethyl acetate, washed with 1N HCl and NaCl solution (sat.) and dried over magnesium sulfate, filtered from the magnesium sulfate, and the ethyl acetate was concentrated on a rotary evaporator. This gave 105 g of 2,4-bismethoxycarbonyloxyacetophenone. 1H NMR (DMSO-D6): 8.05 (d, 1H), 7.38 (d, 1H), 7.36 (s, 1H), 3.86 (d, 6H). The product was used without further purification. 63 g (392 mmol) of bromine in 450 ml of chloroform were added dropwise to the solution of 105 g of 2,4-bismethoxycarbonyloxyacetophenone in chloroform (1000 ml) over the course of 3 h. The reaction was then stirred for a further 15 min at room temperature. The solvent was evaporated on a rotary evaporator. The residue was stirred in ethyl acetate/n-hexane, and the resulting precipitate was filtered off with suction. Recrystallization from ethyl acetate/n-hexane produced 100 g of 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone. 1H NMR (DMSO-D6): 8.11 (d, 1H), 7.42 (m, 2H), 4.87 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H) ppm; m.p. 73-74° C.
126 g (1.66 mmol) of thiourea were introduced into toluene (1000 ml), and 100 g (829 mmol) of pivaloyl chloride were added dropwise. The reaction solution was boiled under reflux for 3 hours, during which two phases formed. The upper phase was decanted off and cooled. The precipitated colorless needles were filtered off with suction and washed with cyclohexane and dried in vacuo. Yield: 64 g. 1H NMR (DMSO-D6): 10.27 (s, 1H), 9.74 (s, 1H), 9.40 (s, 1H), 1.19 (s, 9H) ppm. 107.7 g (310 mmol) of 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone were boiled with 49.7 g (13.6 mmol) of N-pivaloylthiourea and 39.2 g (466 mmol) of NaHCO3 in 1.2 l of ethanol under reflux for 0.5 h. The reaction solution was cooled and admixed with 50.6 g (1.27 mol) of NaOH in 250 ml of water. After stirring for 30 min at room temperature, the reaction solution was taken up with 300 ml of water and neutralized with 2N HCl. The resulting precipitate was filtered off and recrystallized from ethanol/water. 80 g of thiazole were obtained. 1H NMR (DMSO-D6): 11.77 (bs, 1H), 11.02 (bs, 1H), 9.47 (bs, 2H), 7.65 (d, 1H), 7.39 (s, 1H), 6.30 (s, 1H), 6.28 (d, 1H), 1.27 (s, 9H) ppm; m.p. 257-259° C.
114 g (1.5 mol) of thiourea were introduced into toluene (800 ml), and 80 g (0.75 mol) of isobutyryl chloride were added dropwise. The reaction solution was boiled under reflux for 3 hours, during which two phases formed. The upper phase was decanted off and cooled. The precipitated white crystals were filtered off with suction and washed with toluene and dried in vacuo. Yield: 62 g. 1H NMR (DMSO-D6): 11.03 (bs, 1H), 9.66 (bs, 1H), 9.35 (bs, 1H), 2.72 (m, 1H), 1.03 (d, 6H) ppm.
89 g (260 mmol) of 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone were boiled under reflux with 37.5 g (260 mmol) of N-isobutyrylthiourea and 32 g (380 mmol) of NaHCO3 in 1000 ml of ethanol for 0.5 h. The reaction solution was cooled and admixed with 41 g (0.93 mol) of NaOH in 250 ml of water. After stirring for 30 min at room temperature, the reaction solution was taken up with 300 ml of water and adjusted to pH=3 with 2N HCl. The resulting precipitate was filtered off and recrystallized from ethanol/water. 56 g of thiazole were obtained. 1H NMR (DMSO-D6): 12.16 (bs, 1H), 10.88 (bs, 1H), 9.47 (bs, 1H), 7.65 (m, 1H), 7.41 (s, 1H), 6.32 (m, 2H), 2.75 (m, 1H), 1.14 (d, 6H) ppm; m.p. 243-245° C.
143 g (1.88 mol) of thiourea were introduced into toluene (1000 ml), and 100 g (0.93 mol) of n-butyryl chloride were added dropwise. The reaction solution was boiled under reflux for 3 hours, during which two phases formed. The upper phase was decanted off and cooled. The precipitated slightly yellowish crystals were filtered off with suction and washed with toluene and dried in vacuo. Yield: 88 g. 1H NMR (DMSO-D6): 11.03 (bs, 1H), 9.65 (bs, 1H), 9.33 (bs, 1H), 2.33 (t, 2H), 1.53 (m, 2H), 0.86 (t, 3H) ppm; m.p. 115-188° C.
92 g (265 mmol) of 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone were boiled under reflux with 38.75 g (265 mmol) of N-butyrylthiourea and 34 g (397 mmol) of NaHCO3 in 900 ml of ethanol for 0.5 h. The reaction solution was cooled and admixed with 37 g (0.93 mol) of NaOH in 300 ml of water. After stirring for 30 min at room temperature, the reaction solution was taken up with 300 ml of water and neutralized with 2N HCl. The resulting precipitate was filtered off and recrystallized from ethanol/water. 67 g of thiazole were obtained. 1H NMR (DMSO-D6): 12.18 (bs, 1H), 10.89 (bs, 1H), 9.48 (bs, 1H), 7.65 (1 arom. H), 7.40 (s, 1H), 6.31 (2 arom. H), 2.43 (t, 2H), 1.64 (m, 2H), 0.91 (t, 3H) ppm; m.p. 227-229° C.
4.71 g (13.6 mmol) of 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone were boiled under reflux with 1.61 g (13.6 mmol) of N-acetylthiourea and 1.72 g (20.4 mmol) of NaHCO3 in 45 ml of ethanol for 0.5 h. The reaction solution was cooled and admixed with 2.0 g (50 mmol) of NaOH in 20 ml of water. After stirring for 20 min at 0° C., the reaction solution was taken up with 30 ml of water and neutralized with semi-concentrated HCl. The resulting precipitate was filtered off and recrystallized from ethanol/water. 2.73 g of product were obtained. 1H NMR (DMSO-D6): 12.20 (b, 1H), 10.85 (s, 1H), 9.46 (s, 1H), 7.64 (m, 1H), 7.38 (s, 1H), 6.28 (m, 2H), 2.15 (s, 3H) ppm; m.p. 264-264° C.
Procedure analogous to the literature.
BANYU Pharmaceutical Co. Ltd., EP2072519 A1, 2009
Yield: 96%. 1H NMR (DMSO-D6): 12.03 (bs, 1H), 3.85, 3.82 (2×d, 2H), 2.50, 2.47 (2×m, 1H), 2.00 (s, 3H), 0.95-1.90 (m, 9H) ppm
95 g (0.47 mol) of 4-acetoxymethylcyclohexanecarboxylic acid were heated under reflux in 350 ml of thionyl chloride for 2 h. After removing the excess thionyl chloride in vacuo, the residue was taken up in 1 l of toluene, and 71 g (0.94 mol) of thiourea were added. The reaction solution was boiled under reflux for 3 hours and then filtered off while hot. After cooling the mother liquor, the resulting white crystals were filtered off with suction, washed with toluene and dried in vacuo. Yield: 59 g. 1H NMR (DMSO-D6): 11.03, 10.97 (2×s, 1H), 9.64 (bs, 1H), 9.35 (bs, 1H), 3.93, 3.82 (2×d, 2H), 2.61, 2.42 (2×m, 1H), 2.00 (s, 3H), 1.60 (m, 8H), 1.35, 0.94 (2×m, 1H) ppm.
79 g (228 mmol) of 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone were boiled under reflux for 0.5 h with 59 g (228 mmol) of N-(4-acetoxymethylcyclohexylcarbonyl)thiourea and 29 g (340 mmol) of NaHCO3 in 1000 ml of ethanol. The reaction solution was cooled and admixed with 73 g (1.8 mol) of NaOH in 300 ml of water. After stirring for 30 min at room temperature, the reaction solution was taken up with 300 ml of water and adjusted to pH=3 with 2N HCl. The resulting precipitate was filtered off and recrystallized from ethanol/water. 47 g of thiazole were obtained. 1H NMR (DMSO-D6): 12.15, 12.10 (2×s, 1H), 10.96 (2×s, 1H), 9.47 (br, 2H), 7.64 (d, 1H), 7.39 (s, 1H), 6.29 (m, 2H), 4.40 (br, 1H), 3.32, 3.23 (2×d, 2H), 2.65, 2.44 (2×m, 1H), 1.90 (m, 1H), 1.78 (m, 2H), 1.50 (m, 5H), 0.94 (m, 1H) ppm; m.p. 152-160° C.
52 g (0.68 mol) of thiourea were introduced into toluene (500 ml), and 50 g (0.34 mol) of cyclohexanoyl chloride were added dropwise. The reaction solution was boiled under reflux for 3 hours, during which two phases formed. The upper phase was decanted off and cooled. The precipitated crystals were filtered off with suction, washed with toluene and recrystallized from methanol. Yield: 35 g. 1H NMR (DMSO-D6): 10.98 (bs, 1H), 9.65 (bs, 1H), 9.32 (bs, 1H), 2.49 (t, 1H), 1.75 (m, 4H), 1.61 (m, 1H), 1.18 (m, 5H) ppm.
92 g (265 mmol) of 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone were boiled under reflux for 0.5 h with 49.4 g (265 mmol) of N-cyclohexanoylthiourea and 34 g (397 mmol) of NaHCO3 in 900 ml of ethanol. The reaction solution was cooled and admixed with 37 g (930 mmol) of NaOH in 300 ml of water. After stirring for 30 min at room temperature, the reaction solution was taken up with 300 ml of water and neutralized with 2N HCl. The ethanol was largely removed on a rotary evaporator. The precipitate formed was filtered off and recrystallized from ethanol/water. 70 g of thiazole were obtained. 1H NMR (DMSO-D6): 12.14 (bs, 1H), 11.00 (bs, 1H), 9.48 (bs, 1H), 7.64 (1 arom. H), 7.39 (s, 1H), 6.30 (2 arom. H), 2.49 (m, 1H), 1.84 (m, 2H), 1.76 (m, 2H), 1.65 (m, 1H), 1.42 (m, 2H), 1.25 (m, 3H), ppm; m.p.: 262-266° C.
Procedure analogous to the literature.
BANYU Pharmaceutical Co. Ltd., EP2072519 A1, 2009
Yield: 76%. 1H NMR (DMSO-D6): 12.31 (bs, 1H), 7.26 (m, 4H), 5.05 (s, 2H), 3.57 (s, 2H), 2.05 (s, 3H) ppm
3.7 g (18 mmol) of 4-acetoxymethylphenylacetic acid were heated under reflux in 40 ml of thionyl chloride for 2 h. After removing the excess thionyl chloride in vacuo, the residue was taken up in 70 ml of toluene, and 2.7 g (36 mmol) of thiourea were added. The reaction solution was boiled under reflux for 3 hours and then the solvent was removed in vacuo. Purification was by means of column chromatography with cyclohexane/ethyl acetate 1/1 on silica gel. Yield: 2.7 g. 1H NMR (DMSO-D6): 11.29 (bs, 1H), 9.55 (bs, 1H), 9.40 (bs, 1H), 7.30 (m, 4H), 5.04 (s, 2H), 3.71 (s, 2H), 2.05 (s, 3H) ppm.
3.5 g (10 mmol) of 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone were boiled under reflux for 0.5 h with 2.7 g (10 mmol) of N-[2-(4-acetoxymethylphenyl)acetyl]thiourea and 1.3 g (15 mmol) of NaHCO3 in 50 ml of ethanol. The reaction solution was cooled and admixed with 4.0 g (0.1 mol) of NaOH in 20 ml of water. After stirring for 2 h at 60° C., the reaction solution was taken up in 100 ml of water and adjusted to pH=3 with 2N HCl. The resulting precipitate was filtered off and recrystallized from ethanol/water. 1.3 g of thiazole were obtained. 1H NMR (DMSO-D6): 12.44 (s, 1H), 10.80 (s, 1H), 9.48 (s, 1H), 7.66 (d, 1H), 7.41 (s, 1H), 7.29 (m, 4H), 6.32 (m, 2H), 5.13 (t, 1H), 4.47 (d, 2H), 3.77 (s, 2H) ppm; m.p. 254-256° C.
Cosmetic or dermatological preparations with a content of alkylamidothiazoles and their use for the treatment and/or prophylaxis of undesired skin pigmentation are likewise advantageous embodiments of the present invention.
It is particularly advantageous if such preparations comprise 0.000001 to 10% by weight, in particular 0.0001 to 3% by weight, very particularly 0.001 to 1% by weight, of one or more of the alkylamidothiazoles used according to the invention, based on the total weight of the preparation.
Cosmetic and dermatological preparations according to the invention can be in various forms. Thus, they can be e.g. a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W/O) type or of the oil-in-water (O/W) type, a multiple emulsions, for example of the water-in-oil-in-water (W/O/W) type, a gel, a solid stick, a balm or else an aerosol. It is also advantageous according to the invention to administer the substances used according to the invention and/or their derivatives in encapsulated form, e.g. in collagen matrices and other customary encapsulation materials, e.g. as cellulose encapsulations, in gelatin or liposomally encapsulated.
It is also possible and advantageous in the context of the present invention to add the substances used according to the invention and/or their derivatives in aqueous systems or surfactant preparations for cleaning the skin and the hair.
The cosmetic and dermatological preparations according to the invention can comprise cosmetic auxiliaries as are customarily used in such preparations, e.g. preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and/or humectant substances, fats, oils, waxes or other customary constituents of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
The lipid phase can advantageously be selected from the following substance group:
The oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions within the context of the present invention is advantageously selected from the group of esters of saturated and/or unsaturated, branched and/or unbranched alkanecarboxylic acids of chain length from 3 to 30 C atoms and saturated and/or unsaturated, branched and/or unbranched alcohols of chain length from 3 to 30 C atoms, from the group of esters of aromatic carboxylic acids and saturated and/or unsaturated, branched and/or unbranched alcohols of chain length from 3 to 30 C atoms. Such ester oils can then advantageously be selected from the group isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate, and synthetic, semisynthetic and natural mixtures of such esters, e.g. jojoba oil.
The aqueous phase of the preparations according to the invention optionally advantageously comprises humectants such as e.g. propylene glycol, panthenol or hyaluronic acid, and in particular one or more thickeners which can advantageously be selected from the group silicon dioxide, aluminum silicates, hydroxypropylmethylcellulose, particularly advantageously a polyacrylate such as, for example, carbopol grade 980, in each case individually or in combination.
In particular, mixtures of the aforementioned solvents are used. In the case of alcoholic solvents, water can be a further constituent.
Emulsions according to the invention are advantageous and comprise e.g. the specified fats, oils, waxes and other fatty bodies, as well as water and an emulsifier, as is customarily used for such a type of formulation.
Gels according to the invention usually comprise alcohols of low carbon number, e.g. ethanol, propyleglycol, and water or an aforementioned oil in the presence of a thickener which, in the case of oily-alcoholic gels, is preferably silicon dioxide or an aluminum silicate, and in the case of aqueous-alcoholic or alcoholic gels is preferably a polyacrylate.
Suitable propellants for preparations according to the invention that can be sprayed from aerosol containers are the customary known readily volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used on their own or in a mixture with one another. Compressed air is also to be used advantageously.
Moreover, preparations according to the invention can furthermore advantageously comprise substances which serve for preservation, the total amount of the preservatives being e.g. 0.001% by weight to 30% by weight, preferably 0.05 to 10% by weight, in particular 0.1 to 5.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations.
Furthermore, preparations according to the invention can advantageously additionally comprise substances which conceal the troublesome intrinsic odor of the remaining raw materials used, the total amount of the perfume ingredients being e.g. 0.001% by weight to 30% by weight, preferably 0.05 to 10% by weight, in particular 0.1 to 5.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations.
The examples below are intended to illustrate the present invention without limiting it. Unless stated otherwise, all of the quantities, fractions and percentages stated are based on the weight and the total amount or on the total weight of the preparations.
Pyrus Malus Stem Extract
Glycyrrhiza Inflata Root Extract
Butyrospermum Parkii Butter
Butyrospermum Parkii Butter
Glycyrrhiza Inflata root extract
Arctium Lappa root extract
Pimpinella Anisum fruit extract
Prunus Amygdalus Dulcis Oil
Chondrus Crispus
Butyrospermum Parkii Butter
Butyrospermum Parkii Butter
Chondrus Crispus Extract (Carrageenan)
Glycyrrhiza Inflata Root Extract
Persea Gratissima oil
Persea Gratissima oil
Persea Gratissima oil
The liquid phase obtained by mixing together the respective constituents is poured into aerosol containers with a propane/butane mixture (2.7) in the ratio 39:61.
Persea Gratissima oil
| Number | Date | Country | Kind |
|---|---|---|---|
| 10 2013 204 097.0 | Mar 2013 | DE | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2014/052972 | 2/14/2014 | WO | 00 |
